Article
Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2023
Huh Ki Young, Lim Yeji, Yoon Deok Yong, Hwang Jun Gi, Sim Sujin, Kang Jiah, Wang Jangyoung, Kim Mikyung, Jang Seong Bok, Shreeve S Martin, Mehta Jaydeep, Haddish-Berhane Nahor, Oh Jaeseong, Lee SeungHwan, Yu Kyung-Sang
Abstract excerpt
OBJECTIVES: Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild type-sparing third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for advanced non-small cell lung cancer (NSCLC). The study aimed to evaluate the effects of food and race on the pharmacokinetics (PK) of lazertinib from a healthy volunteer trial and PK data from NSCLC patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
